You really need to factor them in and their earnings in any discussion like this. It's still smaller than consumer spending on this stuff was before but it's the growing part.
1,507 karma · joined March 22, 2009
You really need to factor them in and their earnings in any discussion like this. It's still smaller than consumer spending on this stuff was before but it's the growing part.
Have you checked out any international Clinical Trials? You can search a lot of these here: https://clinicaltrials.gov/ getting the filters right can be tricky though. I’d ask AI for some help looking for the right permutations of names for things.
I’d book a call with FCCT as well. They have a list of private vendors that can potentially help with genetic sequencing and a few other things. They also mentioned a service to me that helps you search for potential clinical trials.
- You should pressure test anything an AI says with your doctors, and anything a doctor says with AI.
I have tried out V1 and while it's a bit barebones, the planned features like 'Autocontext' and 'Local-RAG' sound promising. Devil's in the implementation details though.
We believe that in most ETFs right now the transaction costs are largely factored into either the expense ratio or the ETF bid-ask spread, exactly due to the redemption mechanism you discussed. See section titled Spread of the Underlying Securities in an ETF Basket in the following PDF and the following quote:
"If a market maker has to obtain a portion of the ETF constituents on the secondary market to then deliver into the fund as part of the basket process, the cost of acquiring those names should be reflected in the ETFs bid/ask spread — as costs are traditionally passed through to the end customer."
https://www.ssga.com/library-content/pdfs/etf/au/spdr-au-etf...
Also we take estimated spread costs into account when running our portfolio optimization. A higher bid-ask spread as measured by past 1 month NBBO p50 spread generally gets penalized in our portfolio optimization all else being equal, although this depends slightly on what optimization setting you've chosen on Double.
But there are some benefits to doing what you refer to as a "custom one-off fund". Namely we can Tax Loss Harvest any losses and realize those to offset gains we realize in the name of rebalancing. The industry generally calls this direct indexing and wealth clients with $1M and above portfolios have been doing it for years.
We also provide the option of entering a "Buy & Hold" optimization for strategies, which would not rebalance your winners into losers and realizing any gains or losses, but your portfolio will drift over time if you choose this.
We do not hold any funds ourselves. You connect your bank and ach/wire money to an Apex bank account. You can verify your holdings via apex anytime (see: https://help.double.finance/en/articles/10262406-how-can-i-v...)
We take into account tax rates while optimizing your account. You can also chose to put your strategy in Buy & Hold which will never sell anything thus never realize any cap gains.
SIPC protection covers against a brokerage firm failing, which in our case is Apex Clearing. We are not currently a brokerage so SIPC would not apply if Double goes bankrupt.
We currently have 50+ strategies. About 30 of these replicate popular ETFs. MTUM is one of them (https://double.finance/p/explore/124). Here are our 4 factor focused portfolios (https://double.finance/p/explore/factor-thesis). If there are more you want to see please let us know as we can most likely add them.
MIDU is unfortunately not eligible to be traded on a fractional basis by Apex. Main things missing are some new/low volume ETFs and ADRs (although we have some of them).
We are Registered Investment Advisor (RIA) regulated by the SEC.